Alert
This site has not been optimised for Internet Explorer due to Microsoft no longer providing support for the browser. Please view this site using another browser such as Google Chrome or Microsoft Edge.
Te Pū rauemi KOWHEORI-19 COVID-19 resource hub

Support for people working in health during the COVID-19 pandemic. Find information about how you can support yourselves and others, including consumers, teams and colleagues which complements and aligns with Ministry of Health resources.

Kia āta kōwhiri Choosing Wisely

The Choosing Wisely campaign seeks to reduce harm from unnecessary and low-value tests and treatment.

Back to previous page

Ehlers-Danlos syndrome video series: how a multidisciplinary team helped improve patient outcomes

26th January, 2022

This series of videos are about a rare condition called Ehlers-Danlos syndrome, and how working as a multidisciplinary team can improve patient outcomes. The videos include interviews with a consumer, Tracey, and members of the multidisciplinary team that help to manage her condition.

The prolotherapy treatment described within these videos is provided using Food and Drug Administration (FDA) approved sole sclerosing agents off-label, combined with manipulation. This treatment is funded by Medicare in Australia, ACC in New Zealand and within the New Zealand district health board system via Pharmac.

Prolotherapy using agents such as dextrose is not currently publicly funded within New Zealand but there are studies showing benefit. Download a copy of the opinion (660KB, pdf), written by Dr David Rabago from Penn State College of Medicine.

Read more about Tracey and development of these videos: Multidisciplinary team improves care for consumer with rare condition.


Consumer story: Living with Ehlers-Danlos syndrome

Download a copy of the accessible transcript (29KB, docx)


Managing Ehlers-Danlos syndrome: a physician's perspective

Download a copy of the accessible transcript (32KB, docx)


Managing Ehlers-Danlos syndrome: a physiotherapist's perspective

Download a copy of the accessible transcript (29KB, docx)


Managing Ehlers-Danlos syndrome: an osteopath's perspective

Download a copy of the accessible transcript (28KB, docx)


Managing Ehlers-Danlos syndrome: panel discussion part 1

Download a copy of the accessible transcript (33KB, docx)


Managing Ehlers-Danlos syndrome: panel discussion part 2

Download a copy of the accessible transcript (30KB, docx)

 

The prolotherapy treatment described within these videos is provided using Food and Drug Administration (FDA) approved sole sclerosing agents off-label, combined with manipulation. This treatment is funded by Medicare in Australia, ACC in New Zealand and within the New Zealand district health board system via Pharmac.

Prolotherapy using agents such as dextrose is not currently publicly funded within New Zealand but there are studies showing benefit. 


Last updated: 26th January, 2022